FibroGen Inc <FGEN.OQ> expected to post earnings of 2 cents a share - Earnings Preview
FibroGen Inc FGEN.OQ FGEN.O is expected to report results on May 5 (estimated) for the period ending March 31 2025
LSEG's mean analyst estimate for FibroGen Inc is for earnings of 2 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for FibroGen Inc is $10.00, above its last closing price of $0.34.
This summary was machine generated May 2 at 11:08 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Related Articles
Starbucks: The Premium Coffee Brand With a Pressured Bottom Line
TradingKey - Starbucks’ management is projecting confidence in its "Back to Starbucks" turnaround strategy, but the Q2 FY25 results paint a very different picture to investors.
[IN-DEPTH ANALYSIS] Eurozone: EUR/USD Short-Term Outlook – One Word "Rise"; Two Words "Keep Rising"; Three Words "Continue to Rise"
TradingKey - In the short term (0-3 months), the EUR/USD exchange rate is expected to rise, primarily driven by developments on the USD side.
Engineering the Future: TSMC’s Strategic Centrality in the AI Era
TradingKey - In a high-multiple AI news-driven market beset by cyclic concerns regarding semiconductors, Taiwan Semiconductor Manufacturing Company (TSMC) is becoming a less volatile but equally mission-critical AI infrastructure pillar.
